These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9732829)

  • 21. [New in Austria approved specialty drugs and new knowledge regarding currently available specialty drugs. Uroflo].
    Wien Klin Wochenschr; 1995; 107(15):472-6. PubMed ID: 7545857
    [No Abstract]   [Full Text] [Related]  

  • 22. Tamsulosin: real life clinical experience in 19,365 patients.
    Michel MC; Bressel HU; Mehlburger L; Goepel M
    Eur Urol; 1998; 34 Suppl 2():37-45. PubMed ID: 9732827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
    Lee JY; Kim HW; Lee SJ; Koh JS; Suh HJ; Chancellor MB
    BJU Int; 2004 Oct; 94(6):817-20. PubMed ID: 15476515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obstructive primary bladder neck disease: evaluation of the efficacy and safety of alpha1-blockers.
    Cisternino A; Zeccolini G; Calpista A; De Marco V; Prayer Galetti T; Iafrate M; Artibani W
    Urol Int; 2006; 76(2):150-3. PubMed ID: 16493217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia?
    Bèïque L; Por CP; Evans MF
    Can Fam Physician; 1998 Dec; 44():2659-62. PubMed ID: 9870119
    [No Abstract]   [Full Text] [Related]  

  • 26. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study.
    Athanasopoulos A; Gyftopoulos K; Giannitsas K; Fisfis J; Perimenis P; Barbalias G
    J Urol; 2003 Jun; 169(6):2253-6. PubMed ID: 12771763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tamsulosin--the first selective alpha 1A-adrenergic receptor blocker in the treatment of BPH (benign prostatic hypertrophy)].
    Dtsch Med Wochenschr; 1996 Aug; 121(33 Suppl):1-5. PubMed ID: 9022360
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silodosin (Rapaflo) for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2009 Jan; 51(1303):3-4. PubMed ID: 19122568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (Phenylpiperidinyl)cyclohexylsulfonamides: development of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
    Chiu G; Li S; Connolly PJ; Pulito V; Liu J; Middleton SA
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3930-4. PubMed ID: 17517507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha adrenoceptor antagonists in the year 2000: is there anything new?
    Chapple CR
    Curr Opin Urol; 2001 Jan; 11(1):9-16. PubMed ID: 11148741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanding role of alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia.
    Kirby RS
    Int J Clin Pract; 1998 Sep; 52(6):402-7. PubMed ID: 9894377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha-adrenergic blocking drugs in bladder outflow obstruction: what potential has alpha 1-adrenoceptor selectivity?
    Chapple CR
    Br J Urol; 1995 Jul; 76 Suppl 1():47-55. PubMed ID: 7544214
    [No Abstract]   [Full Text] [Related]  

  • 34. Tamsulosin: the United States trials.
    Narayan P
    Geriatrics; 1998 Oct; 53 Suppl 2():S29-32. PubMed ID: 9789483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Benign prostate hyperplasia: success and limitations of pharmacological therapy].
    Madersbacher S; Marszalek M
    Internist (Berl); 2007 Oct; 48(10):1157-64. PubMed ID: 17426942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Most bothersome symptom and symptom specific goal achievement in patients with benign prostatic obstruction: a prospective open label study.
    Lee YS; Lee HN; Han JY; Choo MS; Lee KS
    J Urol; 2011 Mar; 185(3):1003-9. PubMed ID: 21251673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
    Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
    Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of alpha 1-adrenergic receptor subtype selective antagonists on lower urinary tract function in rats with bladder outlet obstruction.
    Gu B; Reiter JP; Schwinn DA; Smith MP; Korstanje C; Thor KB; Dolber PC
    J Urol; 2004 Aug; 172(2):758-62. PubMed ID: 15247777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists.
    Andersson KE
    World J Urol; 2002 Apr; 19(6):390-6. PubMed ID: 12022707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
    Kuritzky L; Rosenberg MT; Sadovsky R
    Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.